dc.contributor.author |
Bazarbachi A. |
dc.contributor.author |
Zelenetz A.D. |
dc.contributor.editor |
|
dc.date |
2014 |
dc.date.accessioned |
2017-10-05T15:38:48Z |
dc.date.available |
2017-10-05T15:38:48Z |
dc.date.issued |
2014 |
dc.identifier |
|
dc.identifier.isbn |
|
dc.identifier.issn |
15401405 |
dc.identifier.uri |
http://hdl.handle.net/10938/16525 |
dc.description.abstract |
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) describe a continuum of cancer care in the United States, from initial diagnosis through treatment and referral to hospice beyond treatment. However, in many other countries, there are no regional or national clinical practice guidelines. In 2008, the NCCN-MENA (Middle East and North Africa) project was launched to adapt the NCCN Guidelines to this part of the world. During their joint presentation at the NCCN 19th Annual Conference, Dr. Ali Bazarbachi and Dr. Andrew D. Zelenetz explored the modification process of NCCN Guidelines for MENA and shared examples of how it improved the care of patients with adult T-cell leukemia or lymphoma and younger patients with diffuse large B-cell lymphoma-regardless of where they live. © JNCCN - Journal of the National Comprehensive Cancer Network. |
dc.format.extent |
|
dc.format.extent |
Pages: (838-841) |
dc.language |
English |
dc.publisher |
Harborside Press; |
dc.relation.ispartof |
Publication Name: JNCCN Journal of the National Comprehensive Cancer Network; Publication Year: 2014; Volume: 12; Pages: (838-841); |
dc.relation.ispartofseries |
|
dc.relation.uri |
|
dc.source |
Scopus |
dc.subject.other |
|
dc.title |
International adaptation and use of NCCN guidelines |
dc.type |
Conference Paper |
dc.contributor.affiliation |
Bazarbachi, A., Department of Medicine, Faculty of Medicine, American University of Beirut, Beirut, Lebanon |
dc.contributor.affiliation |
Zelenetz, A.D., Weill Medical College of Cornell University, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, United States, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Box 330, New York, NY 10065, United States |
dc.contributor.authorAddress |
Bazarbachi, A.; Department of Medicine, Faculty of Medicine, American University of Beirut, Beirut, Lebanon; email: bazarbac@aub.edu.lb |
dc.contributor.authorCorporate |
University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Internal Medicine; |
dc.contributor.authorDepartment |
Internal Medicine |
dc.contributor.authorDivision |
|
dc.contributor.authorEmail |
|
dc.contributor.faculty |
Faculty of Medicine |
dc.contributor.authorInitials |
|
dc.contributor.authorOrcidID |
|
dc.contributor.authorReprintAddress |
|
dc.contributor.authorResearcherID |
|
dc.contributor.authorUniversity |
American University of Beirut Medical Center |
dc.description.cited |
|
dc.description.citedCount |
|
dc.description.citedTotWOSCount |
|
dc.description.citedWOSCount |
|
dc.format.extentCount |
4 |
dc.identifier.articleNo |
|
dc.identifier.coden |
|
dc.identifier.pubmedID |
|
dc.identifier.scopusID |
84902465579 |
dc.identifier.url |
|
dc.publisher.address |
|
dc.relation.ispartofConference |
|
dc.relation.ispartofConferenceCode |
|
dc.relation.ispartofConferenceDate |
|
dc.relation.ispartofConferenceHosting |
|
dc.relation.ispartofConferenceLoc |
|
dc.relation.ispartofConferenceSponsor |
|
dc.relation.ispartofConferenceTitle |
|
dc.relation.ispartofFundingAgency |
|
dc.relation.ispartOfISOAbbr |
|
dc.relation.ispartOfIssue |
|
dc.relation.ispartOfPart |
|
dc.relation.ispartofPubTitle |
JNCCN Journal of the National Comprehensive Cancer Network |
dc.relation.ispartofPubTitleAbbr |
JNCCN J. Nat. Compr. Cancer Netw. |
dc.relation.ispartOfSpecialIssue |
|
dc.relation.ispartOfSuppl |
|
dc.relation.ispartOfVolume |
12 |
dc.source.ID |
|
dc.type.publication |
Series |
dc.subject.otherAuthKeyword |
|
dc.subject.otherChemCAS |
bleomycin, 11056-06-7, 9041-93-4 |
dc.subject.otherChemCAS |
carboplatin, 41575-94-4 |
dc.subject.otherChemCAS |
cyclophosphamide, 50-18-0 |
dc.subject.otherChemCAS |
cytarabine, 147-94-4, 69-74-9 |
dc.subject.otherChemCAS |
doxorubicin, 23214-92-8, 25316-40-9 |
dc.subject.otherChemCAS |
etoposide, 33419-42-0 |
dc.subject.otherChemCAS |
ifosfamide, 3778-73-2 |
dc.subject.otherChemCAS |
methotrexate, 15475-56-6, 59-05-2, 7413-34-5 |
dc.subject.otherChemCAS |
prednisone, 53-03-2 |
dc.subject.otherChemCAS |
rituximab, 174722-31-7 |
dc.subject.otherChemCAS |
vincristine, 57-22-7 |
dc.subject.otherChemCAS |
vindesine, 53643-48-4 |
dc.subject.otherChemCAS |
zidovudine, 30516-87-1 |
dc.subject.otherIndex |
alpha interferon |
dc.subject.otherIndex |
bleomycin |
dc.subject.otherIndex |
carboplatin |
dc.subject.otherIndex |
cyclophosphamide |
dc.subject.otherIndex |
cytarabine |
dc.subject.otherIndex |
doxorubicin |
dc.subject.otherIndex |
etoposide |
dc.subject.otherIndex |
ifosfamide |
dc.subject.otherIndex |
methotrexate |
dc.subject.otherIndex |
prednisone |
dc.subject.otherIndex |
rituximab |
dc.subject.otherIndex |
vincristine |
dc.subject.otherIndex |
vindesine |
dc.subject.otherIndex |
zidovudine |
dc.subject.otherIndex |
cancer combination chemotherapy |
dc.subject.otherIndex |
clinical practice |
dc.subject.otherIndex |
conference paper |
dc.subject.otherIndex |
human |
dc.subject.otherIndex |
international cooperation |
dc.subject.otherIndex |
large cell lymphoma |
dc.subject.otherIndex |
Middle East |
dc.subject.otherIndex |
North Africa |
dc.subject.otherIndex |
oncology |
dc.subject.otherIndex |
patient care |
dc.subject.otherIndex |
practice guideline |
dc.subject.otherIndex |
T cell leukemia |
dc.subject.otherIndex |
United Nations |
dc.subject.otherIndex |
United States |
dc.subject.otherKeywordPlus |
|
dc.subject.otherWOS |
|